Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus

Pharmacotherapy

Volumn 36, Issue 3, 2016, Pages 252-262

  Vu, Anh ^a   Kosmiski, Lisa A ^b   Beitelshees, Amber L ^c   Prigeon, Ronald ^c   Sidhom, Maha S ^a   Bredbeck, Brooke ^a   Predhomme, Julie ^a   Deininger, Kimberly M ^a   Aquilante, Christina L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

adiponectin; low dose; metabolic syndrome; omentin; pioglitazone

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMENTIN; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOQ PROTEIN, HUMAN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE; ANALYSIS; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADIPONECTIN; ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; LECTINS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 84959288318     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1713     Document Type: Article

References (51)

1. Alberti KG, Zimmet P, Shaw J,. The metabolic syndrome-a new worldwide definition. Lancet 2005; 9491: 1059-62.
2. Ford ES, Li C, Sattar N,. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 9: 1898-904.
3. Gami AS, Witt BJ, Howard DE, et al., Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 4: 403-14.
4. Mozumdar A, Liguori G,. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 1: 216-9.
5. Cornier MA, Dabelea D, Hernandez TL, et al., The metabolic syndrome. Endocr Rev 2008; 7: 777-822.
6. Deng Y, Scherer PE,. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 2010; 1212: E1-19.
7. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB,. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 3: 264-80.
8. Pajvani UB, Du X, Combs TP, et al., Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 11: 9073-85.
9. Waki H, Yamauchi T, Kamon J, et al., Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 41: 40352-63.
10. Barseghian A, Gawande D, Bajaj M,. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol 2011; 7: 761-70.
11. Ebinuma H, Miyazaki O, Yago H, Hara K, Yamauchi T, Kadowaki T,. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 2006; 1-2: 47-53.
12. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT,. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 1: 249-59.
13. Tan BK, Adya R, Randeva HS,. Omentin: A novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 5: 143-8.
14. Yang RZ, Lee MJ, Hu H, et al., Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 6: E1253-61.
15. Yki-Jarvinen H,. Thiazolidinediones. N Engl J Med 2004; 11: 1106-18.
16. Aso Y, Hara K, Ozeki N, et al., Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2009; 2: 147-52.
17. Ibanez L, Lopez-Bermejo A, Diaz M, Enriquez G, Valls C, de Zegher F,. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin Endocrinol (Oxf) 2008; 2: 317-20.
18. Liu M, Liu F,. Up- and down-regulation of adiponectin expression and multimerization: mechanisms and therapeutic implication. Biochimie 2012; 10: 2126-30.
19. Maeda N, Takahashi M, Funahashi T, et al., PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 9: 2094-9.
20. Samaha FF, Szapary PO, Iqbal N, et al., Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 3: 624-30.
21. Szapary PO, Bloedon LT, Samaha FF, et al., Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 1: 182-8.
22. DeFronzo RA, Abdul-Ghani M,. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011; 34 (Suppl 2): S202-9.
23. DeFronzo RA, Tripathy D, Schwenke DC, et al., Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 12: 1104-15.
24. Actos (pioglitazone) prescribing information. Available from http://general.takedapharm.com/content/file.aspx?filetypecode=actospi&cacheRandomizer=41c594b3-8348-4e23-8be2-82eb846bfcc0. Accessed December 1, 2015.
25. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL,. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 11: 1605-11.
26. Majima T, Komatsu Y, Doi K, et al., Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J 2006; 3: 325-30.
27. Miyazaki Y, Matsuda M, DeFronzo RA,. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 3: 517-23.
28. Grundy SM, Cleeman JI, Daniels SR, et al., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 17: 2735-52.
29. Alberti KG, Eckel RH, Grundy SM, et al., Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 16: 1640-5.
30. Pacini G, Tonolo G, Sambataro M, et al., Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol 1998; 4 (Pt 1): E592-9.
31. Pacini G, Bergman RN,. MINMOD: A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986; 2: 113-22.
32. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 6: 499-502.
33. Hara K, Horikoshi M, Yamauchi T, et al., Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 6: 1357-62.
34. Iwaki M, Matsuda M, Maeda N, et al., Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 7: 1655-63.
35. Pajvani UB, Hawkins M, Combs TP, et al., Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 13: 12152-62.
36. Tripathy D, Daniele G, Fiorentino TV, et al., Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: A randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 2013; 10: 2153-63.
37. Ohira M, Yamaguchi T, Saiki A, et al., Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin. Diabetes Metab Syndr Obes 2014; 7: 313-9.
38. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M,. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Regul Pept 2013; 182: 1-6.
39. Rajagopalan S, Dutta P, Hota D, Bhansali A, Srinivasan A, Chakrabarti A,. Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial. Diabetes Res Clin Pract 2015; 3: e32-5.
40. Lee HW, Lee HC, Kim BW, et al., Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. Yonsei Med J 2013; 6: 1313-20.
41. Kurisu S, Iwasaki T, Ishibashi K, et al., Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease. J Renin Angiotensin Aldosterone Syst 2013; 1: 51-5.
42. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW,. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 1998; 9: 3169-76.
43. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE,. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 5: 413-23.
44. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT,. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004; 3: 362-5.
45. Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT,. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006; 8: 1057-62.
46. Gutierrez AD, Sathyanarayana P, Konduru S, Ye Y, Birnbaum Y, Bajaj M,. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis 2012; 1: 204-8.
47. Sukhija R, Prayaga S, Marashdeh M, et al., Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009; 3: 495-9.
48. Ridker PM, Danielson E, Fonseca FA, et al., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 21: 2195-207.
49. Sattar N, Preiss D, Murray HM, et al., Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 9716: 735-42.
50. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ,. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 9841: 565-71.
51. Tripathy D, Clement SC, Schwenke DC, et al., Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. Diabetes Care 2014; 6: 1706-11.